|
Session 101-Poster Abstracts
Keys to Successful Outcomes on ART
Wednesday, 2-4 pm; Poster Hall |
507
 |
Predictors and Time Trends of Stably Suppressed Viral Load among HIV-1-infected Individuals on cART in the Swiss HIV Cohort Study
Bruno Ledergerber*1, H Furrer2, M Rickenbach3, M Battegay4, E Bernasconi5, B Hirschel6, M Cavassini7, P Vernazza8, P Francioli3, R Weber1, and the Swiss HIV Cohort Study
1Univ Hosp Zurich, Switzerland; 2Univ Hosp Bern, Switzerland; 3Swiss HIV Cohort Study Data Ctr, Lausanne; 4Univ Hosp Basel, Switzerland; 5Ospedale Regionale di Lugano, Switzerland; 6Univ Hosp Geneva, Switzerland; 7Univ Hosp Lausanne, Switzerland; and 8Cantonal Hosp, St Gallen, Switzerland |
508
|
Relative Effectiveness of Preferred Initial Antiretroviral Regimens in the CFAR Network of Integrated Clinical Systems Cohort
Michael Mugavero*1, B Lau2, H Crane3, J Willig1, M Kitahata3, R Moore2, M Saag1, and CFAR Network of Integrated Clin Systems
1Univ of Alabama at Birmingham, US; 2Johns Hopkins Univ, Baltimore, MD, US; and 3Univ of Washington, Seattle, US |
509
|
Early ART Compared to Deferred ART during Acute Opportunistic Infection Leads to a Reduction in the Systemic Inflammatory Response Resulting in Improved Immunologic Outcomes
Alejandro Sanchez*1, L Komarow2, J Andersen2, A Zolopa3, P Grant3, D Asmuth4, R Pollard4, S Devaraj4, F Sattler1, and ACTG
1Univ of Southern California, Keck Sch of Med, Los Angeles, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Stanford Univ, CA, US; and 4Univ of California, Davis, US |
510
|
A One-pill, Once-daily Fixed-dose Combination of Efavirenz, Emcitrabine, and Tenofovir Disoproxil Fumarate Regimen Is Associated with Higher Unannounced Pill Count Adherence than Non-one-pill, Once-daily Regimens
David Bangsberg*1, K Ragland2, A Monk2, and S Deeks2
1Massachusetts Gen Hosp, Harvard Med Sch, Boston, US and 2Univ of California, San Francisco, US |
511
|
Elvucitabine vs Lamivudine with Tenofovir and Efavirenz in ART-naïve HIV-1-infected Patients: 96-week Final Results
Edwin DeJesus*1, D Saple2, J Morales-Ramirez3, N Kumarasamy4, T Jefferson5, N Bellos6, B Wade7, H Robison8, E Olek8, and ACH443-015 Study Team
1Orlando Immunology Ctr, FL, US; 2Dr Saple’s Clin, Mumbai, India; 3Clin Res Puerto Rico, San Juan; 4YR Gaitonde Ctr for AIDS Res and Ed, Chennai, India; 5Hlth for Life Clin, Little Rock, AR, US; 6Private Practice, Dallas, TX, US; 7Ctr for the Prevention and Treatment of Infections, Pensacola, FL, US; and 8Achillion Pharmaceuticals, Inc, New Haven, CT, US |
512
|
Effect in vitro of CCR5 Antagonists on Innate Immune System: Maraviroc Inhibits the Migration of Neutrophils, Macrophages, and DC
I Sauzullo1, M Lichtner2, F Mengoni1, R Rossi1, A Massetti1, Claudio Mastroianni*2, and V Vullo1
1Sapienza Univ, Rome, Italy and 2Sapienza Univ, Polo Pontino, Latina, Italy |
513
|
Effect of CCL3L1 Copy Number Variation on CD4 Cell Recovery in Treatment-naïve Patients: 96-week Results from the Maraviroc in Treatment-naïve Patients Study
Xiaolan Hu*1, S Hall1, J Wheeler2, C Hyde1, F Sanders3, P Rowe2, J Goodrich4, H Mayer5, and H Valdez5
1Pfizer Inc, Groton, CT, US; 2Quanticate Ltd, Hitchin, UK; 3Pfizer Inc, Sandwich, UK; 4Pfizer Global R&D, New London, CT, US; and 5Pfizer Inc, New York, NY, US |
514
|
Sustained Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination ART in Treatment-naive HIV-1-infected Patients
Eduardo Gotuzzo*1, B-Y Nguyen2, M Markowitz3, F Mendo4, W Ratanasuwan5, C Lu2, J Zhao2, B Homony2, R Barnard2, H Teppler2, and the Protocol 004 Part II Study Team
1Hosp Nacionale Cayetano Heredia, Lima, Peru; 2Merck Res Labs, North Wales, PA, US; 3Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US; 4Hosp Nacionale Edgardo Rebagliati, Lima, Peru; and 5Sriraj Hosp, Bangkok, Thailand |
515
|
Sustained Antiretroviral Effect of Raltegravir at Week 156 in the BENCHMRK Studies and Exploratory Analysis of Late Outcomes Based on Early Virologic Responses
Joseph Eron*1, D Cooper2, R Steigbigel3, B Clotet4, H Wan5, A Meibohm6, P Sklar5, B-Y Nguyen5, H Teppler5, and the BENCHMRK-1 and 2 Study Groups
1Univ of North Carolina at Chapel Hill, US; 2Univ of New South Wales, Sydney, Australia; 3State Univ of New York at Stony Brook, US; 4Hosp Germans Trias i Pujol, Barcelona, Spain; 5Merck Res Labs, North Wales, PA, US; and 6Statistical Consultant, Lafayette Hill, PA, US |
516
|
Similar Immunologic Responses to Modern HAART among IDU and Non-IDU in a Populational Setting
Viviane Lima*, M Hull, S Guillemi, R Barrios, D Milan, B Yip, R Hogg, and J Montaner
BC Ctr for Excellence in HIV/AIDS, St Paul’s Hosp, Vancouver, Canada |
|
